Detail akcie Roche Holding AG Depository Receipt online

Business Summary: Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Roche Holding AG (ADR) revenues increased 2% to SF61.52B. Net income increased 56% to SF12.88B. Revenues reflect United States segment increase of 2% to SF29.5B, Rest of Europe segment increase of 6% to SF10.86B. Net income benefited from Impairment of Goodwill decrease of 99% to SF40M (expense), Impairment of Intangibles - Research/De decrease of 79% to SF222M (expense).